Personalized medicine Europe: Health, genes and society: Tel-Aviv University, Tel-Aviv, Israel, June 19 -21, 2005

David Gurwitz; Gregory Livshits

doi:10.1038/sj.ejhg.5201557

Personalized medicine Europe: Health, genes and society: Tel-Aviv University, Tel-Aviv, Israel, June 19 -21, 2005

David Gurwitz
, Gregory Livshits

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

In summary, we believe that pharmacogenetics will not replace, but enhance, existing good medical practice. A deliberate approach starts with investing more in studies aimed at clarifying relations between genotypes and drug response phenotypes (both safety and efficacy), educating healthcare professionals by illustrating the benefits of pharmacogenomics, and by educating society about the potential benefits for healthcare from the new genomics and proteomics technologies. We feel that the Tel-Aviv workshop on personalized medicine has provided a competent venue for this theme.

Original language	English
Pages (from-to)	376-380
Number of pages	5
Journal	European Journal of Human Genetics
Volume	14
Issue number	3
DOIs	https://doi.org/10.1038/sj.ejhg.5201557
State	Published - Mar 2006
Externally published	Yes

Access to Document

10.1038/sj.ejhg.5201557

Cite this

@article{6ffc9b0b4d9d494ab8ea0af46bf0e4a9,

title = "Personalized medicine Europe: Health, genes and society: Tel-Aviv University, Tel-Aviv, Israel, June 19 -21, 2005",

abstract = "In summary, we believe that pharmacogenetics will not replace, but enhance, existing good medical practice. A deliberate approach starts with investing more in studies aimed at clarifying relations between genotypes and drug response phenotypes (both safety and efficacy), educating healthcare professionals by illustrating the benefits of pharmacogenomics, and by educating society about the potential benefits for healthcare from the new genomics and proteomics technologies. We feel that the Tel-Aviv workshop on personalized medicine has provided a competent venue for this theme.",

author = "David Gurwitz and Gregory Livshits",

note = "Funding Information: The workshop was generously funded by The European Science Foundation; The Yoran Institute for Human Genome Research, Tel-Aviv University; The Adams Brain Research Center, Tel-Aviv University; The Israel Ministry of Science and Technology; Hoffman La-Roche, Switzerland; Teva, Israel; and Dyn Diagnostics, Israel.",

year = "2006",

month = mar,

doi = "10.1038/sj.ejhg.5201557",

language = "אנגלית",

volume = "14",

pages = "376--380",

journal = "European Journal of Human Genetics",

issn = "1018-4813",

publisher = "Springer Nature",

number = "3",

}

TY - JOUR

T1 - Personalized medicine Europe

T2 - Health, genes and society: Tel-Aviv University, Tel-Aviv, Israel, June 19 -21, 2005

AU - Gurwitz, David

AU - Livshits, Gregory

N1 - Funding Information: The workshop was generously funded by The European Science Foundation; The Yoran Institute for Human Genome Research, Tel-Aviv University; The Adams Brain Research Center, Tel-Aviv University; The Israel Ministry of Science and Technology; Hoffman La-Roche, Switzerland; Teva, Israel; and Dyn Diagnostics, Israel.

PY - 2006/3

Y1 - 2006/3

N2 - In summary, we believe that pharmacogenetics will not replace, but enhance, existing good medical practice. A deliberate approach starts with investing more in studies aimed at clarifying relations between genotypes and drug response phenotypes (both safety and efficacy), educating healthcare professionals by illustrating the benefits of pharmacogenomics, and by educating society about the potential benefits for healthcare from the new genomics and proteomics technologies. We feel that the Tel-Aviv workshop on personalized medicine has provided a competent venue for this theme.

AB - In summary, we believe that pharmacogenetics will not replace, but enhance, existing good medical practice. A deliberate approach starts with investing more in studies aimed at clarifying relations between genotypes and drug response phenotypes (both safety and efficacy), educating healthcare professionals by illustrating the benefits of pharmacogenomics, and by educating society about the potential benefits for healthcare from the new genomics and proteomics technologies. We feel that the Tel-Aviv workshop on personalized medicine has provided a competent venue for this theme.

UR - https://www.scopus.com/pages/publications/33645152984

U2 - 10.1038/sj.ejhg.5201557

DO - 10.1038/sj.ejhg.5201557

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 16391560

AN - SCOPUS:33645152984

SN - 1018-4813

VL - 14

SP - 376

EP - 380

JO - European Journal of Human Genetics

JF - European Journal of Human Genetics

IS - 3

ER -

Personalized medicine Europe: Health, genes and society: Tel-Aviv University, Tel-Aviv, Israel, June 19 -21, 2005

Abstract

Access to Document

Other files and links

Fingerprint

Cite this